Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Irwin

Showing results (281-290 of 326) with videos related to

Pageof 33
Sort By:
Cell Reports|April 12, 2025
DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibitionMadeline N Hayes, Sarah Cohen-Gogo, Lynn Kee, et al.
Pediatric Blood & Cancer|January 17, 2026
Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk GroupRebecca J Deyell, Kavitha Srivatsa, Paola Angelini, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2012
Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1Yi Wang, Olga Roche, Chaoying Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Histopathology|February 24, 2025
Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR)Jason A Jarzembowski, Fleur Webster, Klaus Beiske, et al.
EMBO Reports|September 11, 2010
SATB2 augments ΔNp63α in head and neck squamous cell carcinomaJacky Chung, Joanne Lau, Lynn S Cheng, et al.
The Lancet. Oncology|November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion studyMatthias Fischer, Lucas Moreno, David S Ziegler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group DatabaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pediatric Blood & Cancer|November 18, 2020
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group projectLucas Moreno, Dongjing Guo, Meredith S Irwin, et al.
Pageof 33

Showing results (281-290 of 326) with videos related to

Sort By:
Pageof 33
Cell Reports|April 12, 2025
DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibitionMadeline N Hayes, Sarah Cohen-Gogo, Lynn Kee, et al.
Pediatric Blood & Cancer|January 17, 2026
Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk GroupRebecca J Deyell, Kavitha Srivatsa, Paola Angelini, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2012
Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1Yi Wang, Olga Roche, Chaoying Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Histopathology|February 24, 2025
Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR)Jason A Jarzembowski, Fleur Webster, Klaus Beiske, et al.
EMBO Reports|September 11, 2010
SATB2 augments ΔNp63α in head and neck squamous cell carcinomaJacky Chung, Joanne Lau, Lynn S Cheng, et al.
The Lancet. Oncology|November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion studyMatthias Fischer, Lucas Moreno, David S Ziegler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group DatabaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pediatric Blood & Cancer|November 18, 2020
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group projectLucas Moreno, Dongjing Guo, Meredith S Irwin, et al.
Pageof 33